This document is an excerpt from the EUR-Lex website
Document 52021XC0108(02)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 6 January 2021 to 6 January 2021 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 136, 30.4.2004, p. 1.)) 2021/C 6/11
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 6 January 2021 to 6 January 2021 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 136, 30.4.2004, p. 1.)) 2021/C 6/11
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 6 January 2021 to 6 January 2021 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 136, 30.4.2004, p. 1.)) 2021/C 6/11
C/2021/94
OJ C 6, 8.1.2021, p. 13–13
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
8.1.2021 |
EN |
Official Journal of the European Union |
C 6/13 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 6 January 2021 to 6 January 2021
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) )
(2021/C 6/11)
|
— |
Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|